Our results revealed that 10 μM cisplatin or 10 μM cyclophasphamide did not inhibit the cell viability as significantly as combination of LC3 shRNA plasmid transfection and GST treatment did in both human malignant neuroblastoma cell lines. The gene discussed is MAP1LC3A; the disease is cancer.